NCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
Clinical Trials
64 trialsNCT00490139 2025-03-21
ALTTO
Novartis
Phase 3 Completed
NCT00667251 2025-03-21
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT01160211 2025-03-07
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01199367 2024-04-25
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT03500380 2024-02-20
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
RemeGen Co., Ltd.
Phase 2/3 Unknown
NCT03084939 2023-05-06
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00272987 2023-04-28
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Novartis
Phase 3 Terminated
NCT00251433 2023-03-31
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Novartis
Phase 1 Terminated
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT00444535 2021-10-25
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT00508274 2021-09-21
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Novartis
Phase 3 Terminated
NCT00553358 2021-09-21
Neo ALTTO
Novartis
Phase 3 Completed
NCT00073528 2021-02-24
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00367471 2020-09-09
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis
Phase 1 Completed
NCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00820222 2019-04-02
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00320411 2019-01-31
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00477464 2018-09-17
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00371488 2018-08-31
GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00462956 2018-08-31
GW572016 In Patients With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00790816 2018-02-28
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Novartis
Phase 1 Completed
NCT00148902 2017-12-06
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
GlaxoSmithKline
Phase 1 Completed
NCT00258050 2017-12-06
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00169533 2017-11-17
Rollover Study Of Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00388076 2017-11-17
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
GlaxoSmithKline
Phase 1 Completed
NCT00650910 2017-11-17
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00849329 2017-11-14
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00359190 2017-11-13
Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00821054 2017-11-13
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00996762 2017-11-13
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
GlaxoSmithKline
Phase 1 Completed
NCT01205217 2017-06-07
ELATE
GlaxoSmithKline
Phase 2 Withdrawn
NCT00111787 2017-05-31
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01013740 2017-05-31
VITAL
Novartis
Phase 2 Completed
NCT00089999 2017-02-28
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00524303 2016-11-11
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
GlaxoSmithKline
Phase 2 Completed
NCT00829166 2016-10-31
EMILIA
Hoffmann-La Roche
Phase 3 Completed
NCT00422903 2016-05-12
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT00320385 2016-02-26
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01068704 2015-10-12
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00105950 2015-09-28
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01782651 2015-08-10
Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
GlaxoSmithKline
Completed
NCT00075270 2015-05-06
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 3 Completed